还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

                               
登录/注册后可看大图

请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

# n! n- n4 C- @0 j可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  

2 ?# E4 G7 |) `* W5 a
4 Y7 n7 B" H2 N0 `/ XSub-category:
Molecular Targets

( ^8 L- m2 \; V0 }" P/ ~6 ?1 N; D  }
Category:
Tumor Biology
; S; Z* M$ I( T3 s
; ?) j/ i7 I4 Y. P) }7 p
Meeting:
2011 ASCO Annual Meeting
5 j  b& v! _- A3 m2 P8 S

+ \6 b0 u0 V- ^  }Session Type and Session Title:
, k3 K, G7 d( w5 ^7 _Poster Discussion Session, Tumor Biology


2 X' R) `: V# A/ H0 SAbstract No:
2 a- A* t! r$ h5 I' u3 m5 r' r10517
5 N% y1 j' b+ \& m$ J/ Y/ S
2 u2 T' `) K2 R$ ^: |
Citation:
J Clin Oncol 29: 2011 (suppl; abstr 10517)
5 `$ M# W/ \6 V/ n/ g$ b4 O# K/ u
1 x$ [' J9 @2 e" Q) P
9 m5 D9 y2 }1 J: wAuthor(s):
" @0 D4 w. o' `( f8 Y! F+ b& t6 w6 iJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

; z3 E, T$ Q& a4 ~
  m; F1 c- }9 R
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

1 }& X7 X, M0 b* e$ P2 m+ p1 G! M5 }Abstract Disclosures

* k1 A- x" M5 f6 ~Abstract:
/ q- E1 n( ^  Y* R
. M* u8 U. N, O" i" @( n# X
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

; F  a9 [$ x% i  `$ z& P                               
登录/注册后可看大图

; ^. ?3 C0 p1 _" V# [$ R8 m没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

5 o! D: n% U, F' c                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
' @7 u1 Y2 V8 C, qALK一个指标医院要900多 ...

# Z; U% d6 w- ^平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊